Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathophysiology has improved, pharmacological treatments with proven outcomes benefit in HFpEF have been elusive. Indeed, agents with proven efficacy treating reduced ejection fraction (HFrEF), such as Novartis’s Entresto, have consistently fallen short in HFpEF studies. Drug treatment, therefore, focuses on the management of comorbidities, and first-line treatment typically consists of RAAS inhibitors, beta blockers, and diuretics. Unlike in HFrEF patients, calcium channel blockers can be used in this subpopulation. This analysis provides insight into U.S. prescribing patterns for HFpEF.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.